Press releases

• October 21, 2021 - Regulatory press releaseInterim Report for the period July – September 2021
• October 11, 2021 - Other press releaseInvitation to presentation of BioArctic’s Interim Report for the period January – September 2021 on October 21 at 9.30 a.m. CET
• September 28, 2021 - Regulatory press releaseEisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer’s disease under the accelerated approval pathway

Archive

Calendar

• February 3, 2022Full Year Report January-December 2021
• April 28, 2022Interim report January – March 2022
• May 5, 2022Annual General Meeting 2022
• July 12, 2022Interim report January – June 2022
• October 20, 2022Interim report January – September 2022

Read more

Interim Report January - September 2021

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) published the company’s Interim Report for the period January – September 2021 on Thursday, October 21, 2021, at 08:00 a.m. CET.

• Report
• Presentation
• Webcast

Read the report

Alzheimer’s disease

Halting the disease progression would lead to great benefits to patients, families and caregivers.

Read more

Parkinson’s disease

The medical need of treatments is high due to the lack of drugs affecting the underlying pathology.

Read more

Neurodegenerative disorders

BioArctic is committed to help people with neurodegenerative disorders

Read more